Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Harrow Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HROW's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HROW underperformed the US Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: HROW underperformed the US Market which returned 15.6% over the past year.
Price Volatility Vs. Market
How volatile is Harrow Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Harrow Health (NASDAQ:HROW) Using Too Much Debt?
1 month ago | Simply Wall StHow Does Harrow Health's (NASDAQ:HROW) CEO Pay Compare With Company Performance?
2 months ago | Simply Wall StWhat You Need To Know About Harrow Health, Inc.'s (NASDAQ:HROW) Investor Composition
Is Harrow Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HROW ($4.93) is trading below our estimate of fair value ($11.25)
Significantly Below Fair Value: HROW is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HROW is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: HROW is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HROW's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HROW is overvalued based on its PB Ratio (8x) compared to the US Pharmaceuticals industry average (3x).
How is Harrow Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HROW is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HROW is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HROW is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HROW's revenue (25.5% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: HROW's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HROW's Return on Equity is forecast to be high in 3 years time
How has Harrow Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HROW is currently unprofitable.
Growing Profit Margin: HROW is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HROW is unprofitable, but has reduced losses over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare HROW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HROW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).
Return on Equity
High ROE: HROW has a negative Return on Equity (-144.33%), as it is currently unprofitable.
How is Harrow Health's financial position?
Financial Position Analysis
Short Term Liabilities: HROW's short term assets ($30.4M) exceed its short term liabilities ($13.1M).
Long Term Liabilities: HROW's short term assets ($30.4M) exceed its long term liabilities ($21.0M).
Debt to Equity History and Analysis
Debt Level: HROW's debt to equity ratio (114%) is considered high.
Reducing Debt: HROW's debt to equity ratio has reduced from 166.5% to 114% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if HROW has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HROW has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Harrow Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HROW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HROW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HROW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HROW's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HROW's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Baum (47 yo)
Mr. Mark L. Baum, J.D. co-founded Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) and has been its Chief Executive Officer since April 1, 2012. Mr. Baum served as the Chief Executive ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD585.94K).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
|CEO & Director||8.5yrs||US$1.38m||2.49% |
|CFO & Corporate Secretary||5.67yrs||US$1.05m||0.48% |
|President of ImprimisRx||1.67yrs||US$963.80k||0.12% |
|Vice President of Technology||3.42yrs||no data||no data|
|Chief of Formulation Strategy||1.33yrs||no data||no data|
|Chief Medical Officer||1.33yrs||no data||no data|
|Chief Innovation Officer||0.50yr||no data||no data|
Experienced Management: HROW's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|CEO & Director||8.5yrs||US$1.38m||2.49% |
|Independent Director||0.58yr||no data||no data|
|Independent Chairman of the Board||8.5yrs||US$151.50k||3.03% |
|Independent Director||0.083yr||no data||no data|
Experienced Board: HROW's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Harrow Health, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Harrow Health, Inc.
- Ticker: HROW
- Exchange: NasdaqGM
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$126.453m
- Shares outstanding: 25.65m
- Website: https://www.harrowinc.com
Number of Employees
- Harrow Health, Inc.
- 12264 El Camino Real
- Suite 350
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HROW||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Apr 2007|
|3IP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2007|
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulation ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/27 00:38|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.